HRB
57
5
EXC
53
-3
PYPL
54
2
HON
67
2
AON
54
2
VFC
53
5
GIS
31
3
CSX
60
3
GOOG
50
-3
GOOGL
40
-5
JPM
69
2
VMC
57
4
NVDA
56
-4
KMB
39
2
GT
62
6
URBN
56
14
TROW
56
5
MSFT
50
3
LYB
39
2
PG
56
5
HRB
57
5
EXC
53
-3
PYPL
54
2
HON
67
2
AON
54
2
VFC
53
5
GIS
31
3
CSX
60
3
GOOG
50
-3
GOOGL
40
-5
JPM
69
2
VMC
57
4
NVDA
56
-4
KMB
39
2
GT
62
6
URBN
56
14
TROW
56
5
MSFT
50
3
LYB
39
2
PG
56
5
Financhill
Back

Cardlytics 10K Form

Buy
60

CDLX
Cardlytics

Last Price:
3.93
Seasonality Move:
27.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CDLX News And Ratings

See the #1 stock for the next 7 days that we like better than CDLX

CDLX Financial Statistics

Sales & Book Value

Annual Sales: $309.2M
Cash Flow: $-3.87M
Price / Cash Flow: 0
Annual Sales: $1.38
Price / Book: 2.87

Profitability

EPS (TTM): -6.29000
Net Income (TTM): $-274.55M
Gross Margin: $130.38M
Return on Equity: -163.62%
Return on Assets: -50.62%

Cardlytics Earnings Forecast

Key Cardlytics Financial Ratios

  • The Gross Profit Margin over the past 9 years for CDLX is 42.17%.
  • The Selling, General & Administrative Expenses for CDLX have been equal to 37.59% of Gross Profit Margin.
  • The Research & Development expenses have been 16.61% of Revenue.
  • The Interest Expense is -4.59% of Operating Income.
  • The Net Earning history of CDLX is -43.56% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 3 years.

Cardlytics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Media
Sector: Communication Services
Current Symbol: CDLX
CUSIP: 14161W
Website: cardlytics.com

Debt

Debt-to-Equity Ratio: 3.06
Current Ratio: 1.18
Quick Ratio: 1.13

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CDLX Technical Analysis vs Fundamental Analysis

Buy
60
Cardlytics (CDLX) is a Buy

Is Cardlytics a Buy or a Sell?

  • Cardlytics stock is rated a Buy
    The current Cardlytics [CDLX] share price is $3.93. The Score for CDLX is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.